Literature DB >> 19482507

Considering TWEAK as a target for therapy in renal and vascular injury.

Alberto Ortiz1, Ana Belén Sanz, Begoña Muñoz García, Juan Antonio Moreno, Maria Dolores Sánchez Niño, Jose Luis Martín-Ventura, Jesús Egido, Luis Miguel Blanco-Colio.   

Abstract

TWEAK is a cytokine of the TNF superfamily that activates the Fn14 receptor. TWEAK may regulate cell proliferation, cell death, cell differentiation, angiogenesis and inflammation. The expression of TWEAK and Fn14 is increased during vascular and renal injury. Inflammatory cytokines increase Fn14 receptor expression in tubular and vascular smooth muscle cells. Moreover, TWEAK induces tubular cell apoptosis under proinflammatory conditions. TWEAK itself contributes to renal and vascular inflammation by promoting chemokine and inflammatory cytokine secretion. Confirmation of its role in acute kidney injury and atherosclerotic lesions formation came from functional studies in experimental animal models. The available evidence suggests that TWEAK might be a target for therapeutic intervention in renal and vascular injury and its role in different forms of tissue damage should be further explored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482507     DOI: 10.1016/j.cytogfr.2009.05.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  21 in total

Review 1.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

2.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

3.  The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Liviu Ghervan; Diana Moldovan; Alina Potra; Ioan Mihai Patiu; Cosmina Bondor; Mirela Gherman Caprioara
Journal:  Int Urol Nephrol       Date:  2015-10-03       Impact factor: 2.370

4.  One dose of cyclosporine A is protective at initiation of folic acid-induced acute kidney injury in mice.

Authors:  Xiaoyan Wen; Zhiyong Peng; Yingjian Li; Hongzhi Wang; Jeffrey V Bishop; Lisa R Chedwick; Kai Singbartl; John A Kellum
Journal:  Nephrol Dial Transplant       Date:  2012-01-31       Impact factor: 5.992

Review 5.  Tumor necrosis factor-like weak inducer of apoptosis and its potential roles in lupus nephritis.

Authors:  Zhi-Chun Liu; Qiao-Ling Zhou
Journal:  Inflamm Res       Date:  2012-04       Impact factor: 4.575

6.  Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus.

Authors:  Chao Wang; Li-Li Chen; Hai-Feng Pan; Rui-Xue Leng; Wei-Zi Qin; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-10-04       Impact factor: 2.980

7.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

Review 8.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 9.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

Review 10.  Biomarkers for lupus nephritis: a critical appraisal.

Authors:  Chi Chiu Mok
Journal:  J Biomed Biotechnol       Date:  2010-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.